Concepedia

Publication | Open Access

Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium

DOIFull Paper Access

93

Citations

34

References

2013

Year

C. Michel Zwaan, Carmelo Rizzari, Françoise Méchinaud, Donna L. Lancaster, Thomas Lehrnbecher, Vincent H. J. van der Velden, Berna Beverloo, Monique L. den Boer, Rob Pieters, Dirk Reinhardt,
Journal of Clinical Oncology

Abstract

Dasatinib 60 mg/m(2) and 80 mg/m(2) once-daily dosing were selected for phase II studies in children with Ph-positive leukemias.

References

YearCitations

Page 1